Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Cabozantinib Monotherapy in Japanese Patients With Advanced Renal Cell Carcinoma After VEGFR-TKI
jRCT2080223707Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in renal cell carcinoma (RCC), sponsored by Takeda. Primary endpoint: Objective Response Rate. Started Nov 2017; status: completed.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2080223707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223707.